Fig. 1 · Structure

Documents & Downloads

Doxazosin mesylate

Cat. No. A10334 CAS 77883-43-3
Doxazosin mesylate, a quinazoline compound, is an α1-selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia (BPH).

In Stock

Publications for Doxazosin mesylate

1 publication citing this product

  1. L Klem, .et al. , Psychopharmacology (Berl), 2023, Aug;240(8):1629-1650 PMID: 37329343

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
α1-adrenergic receptor

Doxazosin mesylate Research Summary

This section summarizes 3 in vivo studies of Doxazosin mesylate from 1 published reference.

Doxazosin mesylate In Vivo Studies

In female C57BL/6JRj mice, Adooq-sourced doxazosin mesylate produced task-dependent changes in continuous-performance testing. Discriminability improved at 10.00 mg/kg in the variable stimulus duration schedule but did not improve significantly in the variable intertrial interval schedule. Reduced responding coincided with slower reward collection, and a separate locomotor assay showed reduced activity at 3.00 and 10.00 mg/kg. Motor suppression therefore limits interpretation of the behavioral effects. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Doxazosin mesylate in the mouse rCPT vSD schedule

Animal study · Female C57BL/6JRj mice; separate vSD cohort; n=36 reported for DOX in Figure 3 and Tables 2–4 [1]

In the variable stimulus duration schedule, 10.00 mg/kg increased discriminability and accuracy but reduced hit rate; 3.00 and 10.00 mg/kg reduced premature responding. Reward collection was slowed, limiting interpretation as a selective attention effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change in discriminability d′ at 10.00 mg/kg versus vehicleModel estimate ± SE 0.136 ± 0.053; P<0.05[1]
Hit rate, accuracy and premature responding versus vehicleReported result 10.00 mg/kg: hit rate decreased (P<0.001). Accuracy increased at 3.00 (P<0.05) and 10.00 mg/kg (P<0.001). Premature responding decreased at 3.00 (P<0.01) and 10.00 mg/kg (P<0.001).[1]
Reward collection latency versus vehicleReported result Slower at 1.00 mg/kg (P<0.05), 3.00 and 10.00 mg/kg (both P<0.001)[1]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Individual test sessions twice weekly, with at least three days between tests
Treatment course
Counterbalanced Latin square with three doses and an internal vehicle session, flanked by vehicle reference sessions
Vehicle
5% D-glucose and 5% hydroxypropyl-beta-cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DOX dose series versus within-subject vehicle
1.00, 3.00, 10.00 mg/kg
Within-subject vehicle treatment; flanking references included in mixed-model analysisIn the variable stimulus duration schedule, 10.00 mg/kg increased discriminability and accuracy but reduced hit rate; 3.00 and 10.00 mg/kg reduced premature responding. Reward collection was slowed, limiting interpretation as a selective attention effect.[1]
DOX dose series versus within-subject vehicle
Model: Female C57BL/6JRj mice in the vSD schedule
Reported limits: Methods overview says cohorts of 35 and 36; DOX figure/table captions specify 36 per schedule. Exact reconciliation is not given. No lot or SKU specified.
Methods and source locations

Compound reported in the paper: Doxazosin mesylate; Compound label in the paper: DOX

Reported mouse effects of Adooq-sourced doxazosin mesylate under these task conditions; no inference of human cognitive efficacy.

Materials and methods; rCPT analysis; Pharmacological interventions; Results: Variable stimulus duration schedule, Doxazosin; Table 3; Table 4; Figure 3 caption

Change in discriminability d′ at 10.00 mg/kg versus vehicle: Repeated-measures mixed model, post hoc fixed-effect estimate ± SE; d′ not logit-transformed. — Table 3, Discriminability d′, DOX High row; Methods rCPT data analysis

Hit rate, accuracy and premature responding versus vehicle: Repeated-measures mixed model of logit-transformed rate/percentage outcomes. — Results vSD Doxazosin; Table 3 relevant DOX rows

Reward collection latency versus vehicle: Latency analysis versus vehicle; reward latency log-transformed for analysis. — Table 4 vSD DOX Collection row; vSD Doxazosin latency results

DOX dose series versus within-subject vehicle · Materials and methods; rCPT training and testing; Pharmacological interventions; Results: Variable stimulus duration schedule, Doxazosin; Table 3; Table 4; Figure 3 caption

Doxazosin mesylate in the mouse rCPT vITI schedule

Animal study · Female C57BL/6JRj mice; separate vITI cohort; n=36 reported for DOX in Figure 3 and Tables 2–4 [1]

In the variable intertrial interval schedule, 10.00 mg/kg reduced both hit and false-alarm rates, without a significant discriminability improvement. First touches during intertrial intervals fell, but this occurred with slower reward collection and the separately demonstrated motor-depressant effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change in discriminability d′ at 10.00 mg/kg versus vehicleModel estimate ± SE −0.108 ± 0.084; P=0.202[1]
Hit rate, false-alarm rate, accuracy and first touches versus vehicleReported result 10.00 mg/kg: hit rate decreased (P<0.001), false-alarm rate decreased (P<0.01); accuracy increase was a trend (P=0.091). First touches decreased at 3.00 (P<0.01) and 10.00 mg/kg (P<0.001).[1]
Reward collection latency versus vehicleReported result Slower at 1.00 mg/kg (P<0.05), 3.00 and 10.00 mg/kg (both P<0.001)[1]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Individual test sessions twice weekly, with at least three days between tests
Treatment course
Counterbalanced Latin square with three doses and an internal vehicle session, flanked by vehicle reference sessions
Vehicle
5% D-glucose and 5% hydroxypropyl-beta-cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DOX dose series versus within-subject vehicle
1.00, 3.00, 10.00 mg/kg
Within-subject vehicle treatment; flanking references included in mixed-model analysisIn the variable intertrial interval schedule, 10.00 mg/kg reduced both hit and false-alarm rates, without a significant discriminability improvement. First touches during intertrial intervals fell, but this occurred with slower reward collection and the separately demonstrated motor-depressant effect.[1]
DOX dose series versus within-subject vehicle
Model: Female C57BL/6JRj mice in the vITI schedule
Reported limits: Methods overview says cohorts of 35 and 36; DOX figure/table captions specify 36 per schedule. Exact reconciliation is not given. No lot or SKU specified.
Methods and source locations

Compound reported in the paper: Doxazosin mesylate; Compound label in the paper: DOX

Reported mouse effects of Adooq-sourced doxazosin mesylate under these task conditions; no inference of human cognitive efficacy.

Materials and methods; rCPT analysis; Pharmacological interventions; Results: Variable intertrial interval schedule, Doxazosin; Table 2; Table 4; Figure 3 caption

Change in discriminability d′ at 10.00 mg/kg versus vehicle: Repeated-measures mixed model, post hoc fixed-effect estimate ± SE; d′ not logit-transformed. — Table 2, Discriminability d′, DOX High row

Hit rate, false-alarm rate, accuracy and first touches versus vehicle: Repeated-measures mixed model of logit-transformed outcomes. — Results vITI Doxazosin; Table 2 relevant DOX rows

Reward collection latency versus vehicle: Latency analysis versus vehicle; reward latency log-transformed for analysis. — Table 4 vITI DOX Collection row; vITI Doxazosin latency results

DOX dose series versus within-subject vehicle · Materials and methods; rCPT training and testing; Pharmacological interventions; Results: Variable intertrial interval schedule, Doxazosin; Table 2; Table 4; Figure 3 caption

Locomotor control after doxazosin mesylate in mice

Animal study · Female C57BL/6JRj mice pooled from the rCPT cohorts; n=9–10 per dose in Figure 6 caption [1]

Doxazosin reduced distance travelled at 3.00 and 10.00 mg/kg. The 1.00 mg/kg reduction was a trend. These findings limit attribution of reduced rCPT responding to impulsivity alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total distance travelled versus vehicleReported statistics Main effect F(3,33)=9.50, P<0.001; 1.00 mg/kg P=0.091 (trend), 3.00 mg/kg P<0.01, 10.00 mg/kg P<0.001[1]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Each mouse tested twice, at least seven days apart, with different drugs and balanced treatments
Treatment course
Locomotor assessment following the rCPT experiments
Vehicle
5% D-glucose and 5% hydroxypropyl-beta-cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DOX locomotor dose series
1.00, 3.00, 10.00 mg/kg
Vehicle-treated miceDistance travelled decreased significantly at 3.00 and 10.00 mg/kg; trend at 1.00 mg/kg.[1]
DOX locomotor dose series
Model: Pooled female C57BL/6JRj rCPT mice; n=9–10 per dose
Reported limits: No Adooq lot or SKU. This is a follow-up in pooled previously tested animals, not independent replication of the rCPT cohorts.
Methods and source locations

Compound reported in the paper: Doxazosin mesylate; Compound label in the paper: DOX

Mouse locomotor effect under the reported conditions, not a general sedative potency estimate.

Locomotor assay setup and analysis; Pharmacological interventions; Locomotor activity results; Figure 6

Total distance travelled versus vehicle: One-way ANOVA of log-transformed distance, Dunnett comparisons to vehicle; figure shows untransformed mean ± SEM. — Locomotor activity results; Figure 6 and caption

DOX locomotor dose series · Locomotor assay setup and analysis; Pharmacological interventions; Locomotor activity results; Figure 6

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 77883-43-3
Formula C23H25N5O5.CH3SO3H;C24H29N5O8S
Molecular Weight 547.58
SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 14 mg/mL (25.56 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Doxazosin mesylate Research References

  1. [1] Klem L, Nielsen MM, Gestsdóttir SB, et al. Assessing attention and impulsivity in the variable stimulus duration and variable intertrial interval rodent continuous performance test schedules using noradrenaline receptor antagonists in female C57BL/6JRj mice Psychopharmacology (2023). PMID: 37329343 DOI: 10.1007/s00213-023-06385-9 Source material

Publications

1 publication citing this product

  1. L Klem, .et al. , Psychopharmacology (Berl), 2023, Aug;240(8):1629-1650 PMID: 37329343

Added to your cart

View Cart Checkout
Loading...